Overview

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Status:
Active, not recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B cell Lymphoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Brian Hill, MD, PhD
Case Comprehensive Cancer Center
Collaborator:
The Cleveland Clinic
Treatments:
Glycine
Ixazomib
Lenalidomide
Rituximab
Thalidomide